Powerup Acquisition CORP

Aspire Biopharma Holdings, Inc. issued a Form 8-K to clarify the terms of its public warrants (ASPBW) following significant reverse stock splits.

Aspire Biopharma Holdings, Inc. has adjourned its shareholder meeting to June 16, 2026, due to a failure to reach a quorum.

Aspire Biopharma Holdings, Inc. has entered into a definitive agreement to acquire Dura Driver Control Systems for $30 million in cash.

Aspire Biopharma Holdings, Inc. has filed a Form 8-K announcing a 1-for-30 reverse stock split of its common stock, effective May 11, 2026.

Aspire Biopharma Holdings, Inc. announced the closing of its $21 million private placement and a commitment letter for a $22.5 million credit facility to fund the acquisition of Dura Control Systems.

Aspire Biopharma Holdings, Inc. has successfully closed the second tranche of its Series A Convertible Preferred Stock offering, raising $10 million in gross proceeds.

Aspire Biopharma Holdings, Inc. reported a substantial net loss and a 'going concern' warning for Q3 2025, while facing Nasdaq delisting for non-compliance with listing rules.

Aspire Biopharma Holdings, Inc. reported a significant net loss for Q3 2025, alongside progress in its sublingual aspirin clinical trials and ongoing Nasdaq delisting concerns.

Aspire Biopharma Holdings, Inc. reports a significant increase in net loss and accumulated deficit, raising substantial doubt about its ability to continue as a going concern, while also facing Nasdaq delisting threats.

Aspire Biopharma Holdings, Inc. filed an amended quarterly report to correct a $1 million liability understatement, revealing a material weakness in internal controls and significant financial challenges including a going concern doubt and Nasdaq non-compliance.

Aspire Biopharma Holdings reports its first quarterly results post-merger, highlighting a significant net loss and ongoing efforts to develop its sublingual drug delivery technology.

PowerUp Acquisition Corp. reported a net loss for the third quarter of 2024 and is actively pursuing a business combination with Aspire Biopharma after terminating a previous merger agreement.

Aspire Biopharma Holdings, Inc. has filed an amendment to its annual report on Form 10-K for the fiscal year ended December 31, 2025, primarily to include an inadvertently omitted auditor's report.

Aspire Biopharma Holdings finalizes its business combination and is gearing up for clinical trials and FDA Fast Track designation for its high-dose sublingual aspirin product.

PowerUp Acquisition Corp.'s 10-K filing outlines its financials, merger agreement with Visiox Pharmaceuticals, and key operational details.

Aspire Biopharma Holdings, Inc. Director Donald G. Fell filed an amendment to his beneficial ownership statement, clarifying that recent transactions were purchases of company common stock, not dispositions.

Donald G. Fell, a Director at Aspire Biopharma Holdings, Inc., has acquired 20,000 shares of the company's common stock through open market purchases in early June 2025.

PowerUp Acquisition Corp. secures a $500,000 loan facility from Blackstone to support its merger with Aspire Biopharma.

PowerUp Acquisition Corp. and Aspire Biopharma agree to extend the deadline for delivering disclosure schedules as part of their merger agreement to allow for additional due diligence.

PowerUp Acquisition Corp. will pay its sponsor, SRIRAMA Associates, LLC, a $1 million fee upon the successful closing of the Aspire Biopharma business combination to compensate for the risk taken in a prior, terminated deal with Visiox Pharmaceuticals.

PowerUp Acquisition Corp. and Aspire Biopharma amend their merger agreement to adjust the merger consideration, equity incentive plan size, and extend the disclosure schedule delivery date.

Aspire Biopharma Holdings, Inc. is holding a special meeting on June 9, 2026, to seek stockholder approval for warrant-related proposals, including the issuance of shares upon warrant exercise and adjustments to warrant terms.

Aspire Biopharma Holdings, Inc. calls a special meeting to approve a reverse stock split, significant share issuances for capital, and an increase in authorized common stock.

Aspire Biopharma Holdings, Inc. calls a Special Meeting to vote on a reverse stock split to maintain Nasdaq listing and approve the issuance of shares from convertible promissory notes.

PowerUp Acquisition Corp. is seeking shareholder approval to extend the deadline for completing a business combination and remove net tangible asset requirements to facilitate a merger with Visiox Pharmaceuticals, Inc.

Aspire Biopharma Holdings, Inc. is registering for resale up to 159,090,906 shares of common stock issuable upon conversion of Series A Convertible Preferred Stock.

Aspire Biopharma Holdings, Inc. reports significant net losses and going concern doubt, while facing Nasdaq delisting and substantial shareholder dilution from recent financing activities.

Aspire Biopharma Holdings, Inc. files S-1/A to register up to 147 million shares for resale, reporting significant losses and going concern doubt despite positive aspirin clinical trial results.

Aspire Biopharma Holdings, Inc. filed an S-1 registration statement for the resale of up to 147 million common shares underlying convertible promissory notes, while reporting significant losses and a going concern doubt.

Aspire Biopharma Holdings seeks to register the resale of over 11 million shares by selling securityholders, including shares underlying warrants and those issued in connection with a settlement agreement.

Aspire Biopharma Holdings files for the resale of up to 3.15 million shares of common stock following its business combination, including shares issued as commitment shares and those reserved for conversion of convertible debentures.

Alois Ryan Rubenbauer III has reported beneficial ownership of 65,000 shares, representing 5.0% of Aspire Biopharma Holdings, Inc. common stock.

Highbridge Capital Management, LLC has reported beneficial ownership of 5.2% of Aspire Biopharma Holdings, Inc. common stock, primarily through exercisable warrants.

Ardsley Advisory Partners LP and affiliated entities have filed an amendment to their Schedule 13G, reporting 0% beneficial ownership of Aspire Biopharma Holdings.

Ardsley Advisory Partners and affiliated funds have disclosed a 7.76% beneficial ownership stake in Aspire Biopharma Holdings, Inc. common stock.

Lance Friedman has filed an Amendment No. 9 to Schedule 13G, disclosing a 4.52% beneficial ownership stake in Aspire Biopharma Holdings, Inc. as of May 6, 2025.

Harraden Circle Investments and affiliated entities, including Frederick V. Fortmiller, Jr., have significantly reduced their beneficial ownership in Aspire Biopharma Holdings, Inc. to below 5%, triggering an exit filing with the SEC.